These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 6370515)

  • 41. Detection of antibodies to melanocytes in vitiligo by western immunoblotting.
    Hann SK; Shin HK; Park SH; Reynolds SR; Bystryn JC
    Yonsei Med J; 1996 Dec; 37(6):365-70. PubMed ID: 9048487
    [TBL] [Abstract][Full Text] [Related]  

  • 42. On the etiology of vitiligo and gray hair.
    Lerner AB
    Am J Med; 1971 Aug; 51(2):141-7. PubMed ID: 5095523
    [No Abstract]   [Full Text] [Related]  

  • 43. Apoptosis of melanocytes in vitiligo results from antibody penetration.
    Ruiz-Argüelles A; Brito GJ; Reyes-Izquierdo P; Pérez-Romano B; Sánchez-Sosa S
    J Autoimmun; 2007 Dec; 29(4):281-6. PubMed ID: 17888626
    [TBL] [Abstract][Full Text] [Related]  

  • 44. A review and a new hypothesis for non-immunological pathogenetic mechanisms in vitiligo.
    Dell'anna ML; Picardo M
    Pigment Cell Res; 2006 Oct; 19(5):406-11. PubMed ID: 16965269
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Evidence for immunologic mechanisms in human vitiligo: patients' sera induce damage to human melanocytes in vitro by complement-mediated damage and antibody-dependent cellular cytotoxicity.
    Norris DA; Kissinger RM; Naughton GM; Bystryn JC
    J Invest Dermatol; 1988 Jun; 90(6):783-9. PubMed ID: 3373009
    [TBL] [Abstract][Full Text] [Related]  

  • 46. The role of IL-17 in vitiligo: A review.
    Singh RK; Lee KM; Vujkovic-Cvijin I; Ucmak D; Farahnik B; Abrouk M; Nakamura M; Zhu TH; Bhutani T; Wei M; Liao W
    Autoimmun Rev; 2016 Apr; 15(4):397-404. PubMed ID: 26804758
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [Etiopathogenesis of acquired vitiligo].
    Mylek D; Wojas K
    Przegl Dermatol; 1976; 63(5):715-20. PubMed ID: 826985
    [No Abstract]   [Full Text] [Related]  

  • 48. Reactivity to tyrosinase: expression in cancer (melanoma) and autoimmunity (vitiligo).
    Merimsky O; Shoenfeld Y; Baharav E; Zigelman R; Fishman P
    Hum Antibodies Hybridomas; 1996; 7(4):151-6. PubMed ID: 9140726
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [Vitiligo, a cosmetic disturbance or a marker of internal diseases?].
    Estrada Saiz RV; Altallaa A; Estrada Pérez V
    An Med Interna; 1994 Jan; 11(1):1-3. PubMed ID: 8025184
    [No Abstract]   [Full Text] [Related]  

  • 50. The genetics of generalized vitiligo and associated autoimmune diseases.
    Spritz RA
    J Dermatol Sci; 2006 Jan; 41(1):3-10. PubMed ID: 16289692
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Cytolytic antibodies to melanocytes in vitiligo.
    Cui J; Arita Y; Bystryn JC
    J Invest Dermatol; 1993 Jun; 100(6):812-5. PubMed ID: 8496621
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Childhood vitiligo and tacrolimus: immunomodulating treatment for an autoimmune disease.
    Plettenberg H; Assmann T; Ruzicka T
    Arch Dermatol; 2003 May; 139(5):651-4. PubMed ID: 12756103
    [No Abstract]   [Full Text] [Related]  

  • 53. Vitiligo in Zimbabwe.
    Obe WK
    Cent Afr J Med; 1984 Jan; 30(1):259-64. PubMed ID: 6722868
    [No Abstract]   [Full Text] [Related]  

  • 54. The hair follicle melanocytes in vitiligo in relation to disease duration.
    Anbar TS; Abdel-Raouf H; Awad SS; Ragaie MH; Abdel-Rahman AT
    J Eur Acad Dermatol Venereol; 2009 Aug; 23(8):934-9. PubMed ID: 19453793
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Direct evidence to support the role of antigen-specific CD8(+) T cells in melanoma-associated vitiligo.
    Le Gal FA; Avril MF; Bosq J; Lefebvre P; Deschemin JC; Andrieu M; Dore MX; Guillet JG
    J Invest Dermatol; 2001 Dec; 117(6):1464-70. PubMed ID: 11886510
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [Humoral and cellular autoimmunity in genuine vitiligo studied by means of an antigen produced from melanoma cells].
    Höfs T
    Folia Haematol Int Mag Klin Morphol Blutforsch; 1982; 109(2):244-50. PubMed ID: 6179826
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Vitiligo developing in congenital segmental speckled lentiginous nevus: Another example of immunocompromised cutaneous district due to immunological assault on aberrant melanocytes?
    Tiwary AK; Kumar P
    Indian J Dermatol Venereol Leprol; 2017; 83(5):612-614. PubMed ID: 28731015
    [No Abstract]   [Full Text] [Related]  

  • 58. Regulatory T cells in vitiligo: Implications for pathogenesis and therapeutics.
    Dwivedi M; Kemp EH; Laddha NC; Mansuri MS; Weetman AP; Begum R
    Autoimmun Rev; 2015 Jan; 14(1):49-56. PubMed ID: 25308528
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [Vitiligo associated with the acquired immunodeficiency syndrome].
    García-Patos Briones V; Rodríguez Cano L; Capdevila Morell JA; Costells Rodellas A
    Med Clin (Barc); 1994 Sep; 103(9):358. PubMed ID: 7967901
    [No Abstract]   [Full Text] [Related]  

  • 60. Vitiligo: peripheral T-cell subset imbalance as defined by monoclonal antibodies.
    Soubiran P; Benzaken S; Bellet C; Lacour JP; Ortonne JP
    Br J Dermatol; 1985 Jul; 113 Suppl 28():124-7. PubMed ID: 3893518
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.